Paxalisb & ONC 201

I acknowledge buying another tranche of the stock recently - via IG Mar..ts, a broker that I had been with for 15 years. Straight forward, no problem at all, with IG.

It was abit of a shock to see this de listing advice from the NASDAG - but on the only side, it may mean the company has to go on the market and maybe....... just maybe sell for 10 times more, than its current cap.

Anyway back with more content and detail again in these postings. .....This info down below, might be the best so far. All double checked ....and most importantly it is a imminent situation, which could see significant revenue soon. Once again, I will forward the post to the company. This is real and MUST be worked on, by the company....too much at stake and seemingly no investor should excuse them for inaction here. See what you think....

Condensed and to the point....
-----------------------------
There are no drugs approved for DIPG....but Chimerix (and their drug ONC201)....was just taken over for nearly one billion US dollars, and the FDA has advised Jazz (new owners of the drug) of a marketing approval decision by 19th Aug.

Chimerix clinical FDA studies for ONC201 .......only focuses on patients with brain tumors that contain the H3 K27M mutation. But in fact 50% or more DIPG cancer, also harbour the TP53 tumor gene suppressor.  

ONC 201 does not work on the DIPG TP53 gene......(or 50% of DIPG). Thus, all the work of Dr Dunn and that world consortium work ....ONC 201 and paxalisib in combo for all DIPG patients. ie  (containing bothH3K27M & TP53 mutations)

Chimerix make much of their revenue generation from compassionate sale of ONC 201 over the years. In fact, Dr Dunn paid $80,000 for ONC201 out of Germany for his daughter.

Given approval by the FDA of ONC 201 soon (to justify the billion dollar spend by Jazz)......and vast amounts of world class research on the Internet for combo ONC201 Paxalisib studies in TP53 DIPG - even paediatric neuro-oncologist in the world, would seek out Paxalisib..... where their patient has TP53 DIPG mutation.

Certainly there is well documented evidence of compassionate use programs & associated revenues- even more so in such a disease for children / ONC 201 being the first drug approved .....and all this world best research for what paxalisib may add to help the kids....in TP53 DIPG.

So as mentioned, I will send it on to the company. I would hope and think, this exact proposition is under consideration by the company.....right now. Far, far more is at stake than investor returns - and nobody who is a clear thinker should greet such an idea with anything but enthusiasm.